drugset / Trial / NCT03103490

18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation

NCT03103490

Phase 2 Terminated 45 enrolled Stanford University GE Healthcare · collab
NaSingle-groupOpen-labelDiagnostic

Summary

The investigators will evaluate the detection of cardiac sarcoidosis or inflammation using 18F-FSPG PET/MRI (or PET/CT for participants with metal implants).

Timeline

Start
2017-08-02
Primary completion
2021-09-28
Completion
2021-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FSPG Diagnostic / imaging agent 296 mbq Intravenous